Healthcare >> CEO Interviews >> February 18, 2002

Daniel Burgess – Hollis-eden Pharmaceuticals Inc (heph)

DANIEL D. BURGESS became Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., in August 1999. Mr. Burgess joined Hollis-Eden from Nanogen Inc., where he served as Vice President and Chief Financial Officer. Prior to joining Nanogen, Mr. Burgess spent 10 years with Gensia Sicor, Inc. (now Sicor, Inc.) and Gensia Automedics, Inc., a partially owned subsidiary of Gensia Sicor. He served as President and a Director of Gensia Automedics, where he was responsible for all functional areas of this medical products company. In addition, he was Vice President and Chief Financial Officer of Gensia Sicor, where he was responsible for finance, investor relations, business development and other administrative functions. During his tenure with Gensia, Mr. Burgess helped transform the company from a research stage company with less than 50 employees into a fully integrated specialty pharmaceutical company with more than $150 million in annual revenues. Mr. Burgess was instrumental in helping Gensia raise over $400 million in various public and private financings and was a key figure in a number of acquisitions and in-licensing and out-licensing transactions. Prior to joining Gensia, Mr. Burgess held positions at Castle & Cooke, Inc., and Smith Barney, Harris Upham and Company. He received a degree in economics from Stanford University and an MBA from Harvard Business School. Profile
TWST: May we begin with a brief historical sketch of Hollis-Eden and a

picture of what you're doing at the company at the present time?

Mr. Burgess: Hollis-Eden was founded in 1994. We are